Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab.
Kreft
Burkhard
B
Wohlrab
Johannes
J
Bramsiepe
Isa
I
Eismann
Regina
R
Winkler
Matthias
M
Marsch
Wolfgang Christian
WC
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects; D003879:Dermatologic Agents / Q000627:therapeutic use*; D000077613:Etoricoxib; D006801:Humans; D000069285:Infliximab; D008297:Male; D011725:Pyridines / Q000009:adverse effects; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy* / Q000209:etiology; D013450:Sulfones / Q000009:adverse effects; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D052246:Cyclooxygenase 2 Inhibitors; D003879:Dermatologic Agents; D011725:Pyridines; D013450:Sulfones; D000069285:Infliximab; D000077613:Etoricoxib